English
简体中文
Total: £ 56.28
Published Date: 2026-03-31 | Pages: 125 | Tables: 123 | Medical Care
The global Patient-derived Xenograft (PDX) Models market was valued at US$ 417 million in 2025 and is anticipated to reach US$ 735 million by 2032, at a CAGR of 8.5% from 2026 to 2032.
Global top 5 manufacturers of patient-derived xenograft (PDX) models occupied for a share nearly 45 percent, key players are Crown Bioscience, Champions Oncology, Wuxi Apptec, EPO Berlin-Buch, and Oncodesign, etc. Geographically speaking, Asia Pacific holds the most of global market share, about 35%. North America holds about 30% of share, while Europe followed by nearly 20%. In terms of type, mouse model accounted for nearly 75%, and rat model accounted for a share of 25%,The application of patient-derived xenograft (PDX) models includes preclinical drug development and biomarker analysis. Preclinical drug development shares over 75%, while biomarker analysis shares about 20%.
This report delivers a comprehensive overview of the global Patient-derived Xenograft (PDX) Models market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Patient-derived Xenograft (PDX) Models. The Patient-derived Xenograft (PDX) Models market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Patient-derived Xenograft (PDX) Models market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Patient-derived Xenograft (PDX) Models manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Crown Bioscience
Champions Oncology
Wuxi Apptec
The Jackson Laboratory
EPO Berlin-Buch
Oncodesign
Xentech
Envigo
Charles River Laboratories
Pharmatest Services
Urosphere
MEDICILON
Horizon Discovery
Shanghai Model Organisms Center
GemPharmatech
LIDE Biotech
Segment by Type
Mouse Model
Rat Model
Segment by Application
Preclinical Drug development
Biomarker Analysis
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Patient-derived Xenograft (PDX) Models companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Patient-derived Xenograft (PDX) Models Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Mouse Model
1.2.3 Rat Model
1.3 Market by Application
1.3.1 Global Patient-derived Xenograft (PDX) Models Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Preclinical Drug development
1.3.3 Biomarker Analysis
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Patient-derived Xenograft (PDX) Models Market Perspective (2021–2032)
2.2 Global Patient-derived Xenograft (PDX) Models Growth Trends by Region
2.2.1 Global Patient-derived Xenograft (PDX) Models Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Patient-derived Xenograft (PDX) Models Historic Market Size by Region (2021–2026)
2.2.3 Patient-derived Xenograft (PDX) Models Forecasted Market Size by Region (2027–2032)
2.3 Patient-derived Xenograft (PDX) Models Market Dynamics
2.3.1 Patient-derived Xenograft (PDX) Models Industry Trends
2.3.2 Patient-derived Xenograft (PDX) Models Market Drivers
2.3.3 Patient-derived Xenograft (PDX) Models Market Challenges
2.3.4 Patient-derived Xenograft (PDX) Models Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Patient-derived Xenograft (PDX) Models Players by Revenue
3.1.1 Global Top Patient-derived Xenograft (PDX) Models Players by Revenue (2021–2026)
3.1.2 Global Patient-derived Xenograft (PDX) Models Revenue Market Share by Players (2021–2026)
3.2 Global Top Patient-derived Xenograft (PDX) Models Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Patient-derived Xenograft (PDX) Models Revenue
3.4 Global Patient-derived Xenograft (PDX) Models Market Concentration Ratio
3.4.1 Global Patient-derived Xenograft (PDX) Models Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Patient-derived Xenograft (PDX) Models Revenue in 2025
3.5 Global Key Players of Patient-derived Xenograft (PDX) Models Head Offices and Areas Served
3.6 Global Key Players of Patient-derived Xenograft (PDX) Models, Products and Applications
3.7 Global Key Players of Patient-derived Xenograft (PDX) Models, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Patient-derived Xenograft (PDX) Models Breakdown Data by Type
4.1 Global Patient-derived Xenograft (PDX) Models Historic Market Size by Type (2021–2026)
4.2 Global Patient-derived Xenograft (PDX) Models Forecasted Market Size by Type (2027–2032)
5 Patient-derived Xenograft (PDX) Models Breakdown Data by Application
5.1 Global Patient-derived Xenograft (PDX) Models Historic Market Size by Application (2021–2026)
5.2 Global Patient-derived Xenograft (PDX) Models Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Patient-derived Xenograft (PDX) Models Market Size (2021–2032)
6.2 North America Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Patient-derived Xenograft (PDX) Models Market Size by Country (2021–2026)
6.4 North America Patient-derived Xenograft (PDX) Models Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Patient-derived Xenograft (PDX) Models Market Size (2021–2032)
7.2 Europe Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Patient-derived Xenograft (PDX) Models Market Size by Country (2021–2026)
7.4 Europe Patient-derived Xenograft (PDX) Models Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size (2021–2032)
8.2 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region (2021–2026)
8.4 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Patient-derived Xenograft (PDX) Models Market Size (2021–2032)
9.2 Latin America Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Patient-derived Xenograft (PDX) Models Market Size by Country (2021–2026)
9.4 Latin America Patient-derived Xenograft (PDX) Models Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size (2021–2032)
10.2 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country (2021–2026)
10.4 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Crown Bioscience
11.1.1 Crown Bioscience Company Details
11.1.2 Crown Bioscience Business Overview
11.1.3 Crown Bioscience Patient-derived Xenograft (PDX) Models Introduction
11.1.4 Crown Bioscience Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.1.5 Crown Bioscience Recent Development
11.2 Champions Oncology
11.2.1 Champions Oncology Company Details
11.2.2 Champions Oncology Business Overview
11.2.3 Champions Oncology Patient-derived Xenograft (PDX) Models Introduction
11.2.4 Champions Oncology Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.2.5 Champions Oncology Recent Development
11.3 Wuxi Apptec
11.3.1 Wuxi Apptec Company Details
11.3.2 Wuxi Apptec Business Overview
11.3.3 Wuxi Apptec Patient-derived Xenograft (PDX) Models Introduction
11.3.4 Wuxi Apptec Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.3.5 Wuxi Apptec Recent Development
11.4 The Jackson Laboratory
11.4.1 The Jackson Laboratory Company Details
11.4.2 The Jackson Laboratory Business Overview
11.4.3 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Introduction
11.4.4 The Jackson Laboratory Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.4.5 The Jackson Laboratory Recent Development
11.5 EPO Berlin-Buch
11.5.1 EPO Berlin-Buch Company Details
11.5.2 EPO Berlin-Buch Business Overview
11.5.3 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Introduction
11.5.4 EPO Berlin-Buch Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.5.5 EPO Berlin-Buch Recent Development
11.6 Oncodesign
11.6.1 Oncodesign Company Details
11.6.2 Oncodesign Business Overview
11.6.3 Oncodesign Patient-derived Xenograft (PDX) Models Introduction
11.6.4 Oncodesign Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.6.5 Oncodesign Recent Development
11.7 Xentech
11.7.1 Xentech Company Details
11.7.2 Xentech Business Overview
11.7.3 Xentech Patient-derived Xenograft (PDX) Models Introduction
11.7.4 Xentech Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.7.5 Xentech Recent Development
11.8 Envigo
11.8.1 Envigo Company Details
11.8.2 Envigo Business Overview
11.8.3 Envigo Patient-derived Xenograft (PDX) Models Introduction
11.8.4 Envigo Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.8.5 Envigo Recent Development
11.9 Charles River Laboratories
11.9.1 Charles River Laboratories Company Details
11.9.2 Charles River Laboratories Business Overview
11.9.3 Charles River Laboratories Patient-derived Xenograft (PDX) Models Introduction
11.9.4 Charles River Laboratories Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.9.5 Charles River Laboratories Recent Development
11.10 Pharmatest Services
11.10.1 Pharmatest Services Company Details
11.10.2 Pharmatest Services Business Overview
11.10.3 Pharmatest Services Patient-derived Xenograft (PDX) Models Introduction
11.10.4 Pharmatest Services Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.10.5 Pharmatest Services Recent Development
11.11 Urosphere
11.11.1 Urosphere Company Details
11.11.2 Urosphere Business Overview
11.11.3 Urosphere Patient-derived Xenograft (PDX) Models Introduction
11.11.4 Urosphere Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.11.5 Urosphere Recent Development
11.12 MEDICILON
11.12.1 MEDICILON Company Details
11.12.2 MEDICILON Business Overview
11.12.3 MEDICILON Patient-derived Xenograft (PDX) Models Introduction
11.12.4 MEDICILON Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.12.5 MEDICILON Recent Development
11.13 Horizon Discovery
11.13.1 Horizon Discovery Company Details
11.13.2 Horizon Discovery Business Overview
11.13.3 Horizon Discovery Patient-derived Xenograft (PDX) Models Introduction
11.13.4 Horizon Discovery Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.13.5 Horizon Discovery Recent Development
11.14 Shanghai Model Organisms Center
11.14.1 Shanghai Model Organisms Center Company Details
11.14.2 Shanghai Model Organisms Center Business Overview
11.14.3 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Introduction
11.14.4 Shanghai Model Organisms Center Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.14.5 Shanghai Model Organisms Center Recent Development
11.15 GemPharmatech
11.15.1 GemPharmatech Company Details
11.15.2 GemPharmatech Business Overview
11.15.3 GemPharmatech Patient-derived Xenograft (PDX) Models Introduction
11.15.4 GemPharmatech Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.15.5 GemPharmatech Recent Development
11.16 LIDE Biotech
11.16.1 LIDE Biotech Company Details
11.16.2 LIDE Biotech Business Overview
11.16.3 LIDE Biotech Patient-derived Xenograft (PDX) Models Introduction
11.16.4 LIDE Biotech Revenue in Patient-derived Xenograft (PDX) Models Business (2021–2026)
11.16.5 LIDE Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Patient-derived Xenograft (PDX) Models Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Mouse Model
Table 3. Key Players of Rat Model
Table 4. Global Patient-derived Xenograft (PDX) Models Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Patient-derived Xenograft (PDX) Models Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Patient-derived Xenograft (PDX) Models Market Size by Region (US$ Million), 2021–2026
Table 7. Global Patient-derived Xenograft (PDX) Models Market Share by Region (2021–2026)
Table 8. Global Patient-derived Xenograft (PDX) Models Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Patient-derived Xenograft (PDX) Models Market Share by Region (2027–2032)
Table 10. Patient-derived Xenograft (PDX) Models Market Trends
Table 11. Patient-derived Xenograft (PDX) Models Market Drivers
Table 12. Patient-derived Xenograft (PDX) Models Market Challenges
Table 13. Patient-derived Xenograft (PDX) Models Market Restraints
Table 14. Global Patient-derived Xenograft (PDX) Models Revenue by Players (US$ Million), 2021–2026
Table 15. Global Patient-derived Xenograft (PDX) Models Market Share by Players (2021–2026)
Table 16. Global Top Patient-derived Xenograft (PDX) Models Players by Tier (Tier 1, Tier 2, and Tier 3), based on Patient-derived Xenograft (PDX) Models Revenue, 2025
Table 17. Ranking of Global Top Patient-derived Xenograft (PDX) Models Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Patient-derived Xenograft (PDX) Models Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Patient-derived Xenograft (PDX) Models, Headquarters and Area Served
Table 20. Global Key Players of Patient-derived Xenograft (PDX) Models, Products and Applications
Table 21. Global Key Players of Patient-derived Xenograft (PDX) Models, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Patient-derived Xenograft (PDX) Models Market Size by Type (US$ Million), 2021–2026
Table 24. Global Patient-derived Xenograft (PDX) Models Revenue Market Share by Type (2021–2026)
Table 25. Global Patient-derived Xenograft (PDX) Models Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Patient-derived Xenograft (PDX) Models Revenue Market Share by Type (2027–2032)
Table 27. Global Patient-derived Xenograft (PDX) Models Market Size by Application (US$ Million), 2021–2026
Table 28. Global Patient-derived Xenograft (PDX) Models Revenue Market Share by Application (2021–2026)
Table 29. Global Patient-derived Xenograft (PDX) Models Forecasted Market Size by Application (US$ Million), 2027–2032
Table 30. Global Patient-derived Xenograft (PDX) Models Revenue Market Share by Application (2027–2032)
Table 31. North America Patient-derived Xenograft (PDX) Models Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Patient-derived Xenograft (PDX) Models Market Size by Country (US$ Million), 2021–2026
Table 33. North America Patient-derived Xenograft (PDX) Models Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Patient-derived Xenograft (PDX) Models Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Patient-derived Xenograft (PDX) Models Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Patient-derived Xenograft (PDX) Models Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Patient-derived Xenograft (PDX) Models Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Patient-derived Xenograft (PDX) Models Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Patient-derived Xenograft (PDX) Models Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country (US$ Million), 2027–2032
Table 46. Crown Bioscience Company Details
Table 47. Crown Bioscience Business Overview
Table 48. Crown Bioscience Patient-derived Xenograft (PDX) Models Product
Table 49. Crown Bioscience Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 50. Crown Bioscience Recent Development
Table 51. Champions Oncology Company Details
Table 52. Champions Oncology Business Overview
Table 53. Champions Oncology Patient-derived Xenograft (PDX) Models Product
Table 54. Champions Oncology Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 55. Champions Oncology Recent Development
Table 56. Wuxi Apptec Company Details
Table 57. Wuxi Apptec Business Overview
Table 58. Wuxi Apptec Patient-derived Xenograft (PDX) Models Product
Table 59. Wuxi Apptec Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 60. Wuxi Apptec Recent Development
Table 61. The Jackson Laboratory Company Details
Table 62. The Jackson Laboratory Business Overview
Table 63. The Jackson Laboratory Patient-derived Xenograft (PDX) Models Product
Table 64. The Jackson Laboratory Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 65. The Jackson Laboratory Recent Development
Table 66. EPO Berlin-Buch Company Details
Table 67. EPO Berlin-Buch Business Overview
Table 68. EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Product
Table 69. EPO Berlin-Buch Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 70. EPO Berlin-Buch Recent Development
Table 71. Oncodesign Company Details
Table 72. Oncodesign Business Overview
Table 73. Oncodesign Patient-derived Xenograft (PDX) Models Product
Table 74. Oncodesign Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 75. Oncodesign Recent Development
Table 76. Xentech Company Details
Table 77. Xentech Business Overview
Table 78. Xentech Patient-derived Xenograft (PDX) Models Product
Table 79. Xentech Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 80. Xentech Recent Development
Table 81. Envigo Company Details
Table 82. Envigo Business Overview
Table 83. Envigo Patient-derived Xenograft (PDX) Models Product
Table 84. Envigo Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 85. Envigo Recent Development
Table 86. Charles River Laboratories Company Details
Table 87. Charles River Laboratories Business Overview
Table 88. Charles River Laboratories Patient-derived Xenograft (PDX) Models Product
Table 89. Charles River Laboratories Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 90. Charles River Laboratories Recent Development
Table 91. Pharmatest Services Company Details
Table 92. Pharmatest Services Business Overview
Table 93. Pharmatest Services Patient-derived Xenograft (PDX) Models Product
Table 94. Pharmatest Services Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 95. Pharmatest Services Recent Development
Table 96. Urosphere Company Details
Table 97. Urosphere Business Overview
Table 98. Urosphere Patient-derived Xenograft (PDX) Models Product
Table 99. Urosphere Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 100. Urosphere Recent Development
Table 101. MEDICILON Company Details
Table 102. MEDICILON Business Overview
Table 103. MEDICILON Patient-derived Xenograft (PDX) Models Product
Table 104. MEDICILON Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 105. MEDICILON Recent Development
Table 106. Horizon Discovery Company Details
Table 107. Horizon Discovery Business Overview
Table 108. Horizon Discovery Patient-derived Xenograft (PDX) Models Product
Table 109. Horizon Discovery Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 110. Horizon Discovery Recent Development
Table 111. Shanghai Model Organisms Center Company Details
Table 112. Shanghai Model Organisms Center Business Overview
Table 113. Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Product
Table 114. Shanghai Model Organisms Center Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 115. Shanghai Model Organisms Center Recent Development
Table 116. GemPharmatech Company Details
Table 117. GemPharmatech Business Overview
Table 118. GemPharmatech Patient-derived Xenograft (PDX) Models Product
Table 119. GemPharmatech Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 120. GemPharmatech Recent Development
Table 121. LIDE Biotech Company Details
Table 122. LIDE Biotech Business Overview
Table 123. LIDE Biotech Patient-derived Xenograft (PDX) Models Product
Table 124. LIDE Biotech Revenue in Patient-derived Xenograft (PDX) Models Business (US$ Million), 2021–2026
Table 125. LIDE Biotech Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
Table 129. Authors List of This Report
List of Figures
Figure 1. Patient-derived Xenograft (PDX) Models Picture
Figure 2. Global Patient-derived Xenograft (PDX) Models Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Patient-derived Xenograft (PDX) Models Market Share by Type: 2025 vs 2032
Figure 4. Mouse Model Features
Figure 5. Rat Model Features
Figure 6. Global Patient-derived Xenograft (PDX) Models Market Size by Application (US$ Million), 2021–2032
Figure 7. Global Patient-derived Xenograft (PDX) Models Market Share by Application: 2025 vs 2032
Figure 8. Preclinical Drug development Case Studies
Figure 9. Biomarker Analysis Case Studies
Figure 10. Patient-derived Xenograft (PDX) Models Report Years Considered
Figure 11. Global Patient-derived Xenograft (PDX) Models Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 12. Global Patient-derived Xenograft (PDX) Models Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Patient-derived Xenograft (PDX) Models Market Share by Region: 2025 vs 2032
Figure 14. Global Patient-derived Xenograft (PDX) Models Market Share by Players in 2025
Figure 15. Global Patient-derived Xenograft (PDX) Models Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 16. The Top 10 and 5 Players Market Share by Patient-derived Xenograft (PDX) Models Revenue in 2025
Figure 17. North America Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 18. North America Patient-derived Xenograft (PDX) Models Market Share by Country (2021–2032)
Figure 19. United States Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. Canada Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. Europe Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Europe Patient-derived Xenograft (PDX) Models Market Share by Country (2021–2032)
Figure 23. Germany Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. France Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. U.K. Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Italy Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Russia Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Ireland Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Asia-Pacific Patient-derived Xenograft (PDX) Models Market Share by Region (2021–2032)
Figure 31. China Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Japan Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. South Korea Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Southeast Asia Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. India Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Australia & New Zealand Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Latin America Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Latin America Patient-derived Xenograft (PDX) Models Market Share by Country (2021–2032)
Figure 39. Mexico Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Brazil Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Middle East & Africa Patient-derived Xenograft (PDX) Models Market Share by Country (2021–2032)
Figure 43. Israel Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Saudi Arabia Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. UAE Patient-derived Xenograft (PDX) Models Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Crown Bioscience Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 47. Champions Oncology Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 48. Wuxi Apptec Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 49. The Jackson Laboratory Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 50. EPO Berlin-Buch Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 51. Oncodesign Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 52. Xentech Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 53. Envigo Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 54. Charles River Laboratories Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 55. Pharmatest Services Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 56. Urosphere Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 57. MEDICILON Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 58. Horizon Discovery Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 59. Shanghai Model Organisms Center Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 60. GemPharmatech Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 61. LIDE Biotech Revenue Growth Rate in Patient-derived Xenograft (PDX) Models Business (2021–2026)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
